Alpine Immune Sciences Inc
NASDAQ:ALPN
Alpine Immune Sciences Inc
Revenue
Alpine Immune Sciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alpine Immune Sciences Inc
NASDAQ:ALPN
|
Revenue
$58.9m
|
CAGR 3-Years
85%
|
CAGR 5-Years
142%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Alpine Immune Sciences Inc
Revenue Breakdown
Breakdown by Geography
Alpine Immune Sciences Inc
Breakdown by Segments
Alpine Immune Sciences Inc
See Also
What is Alpine Immune Sciences Inc's Revenue?
Revenue
58.9m
USD
Based on the financial report for Dec 31, 2023, Alpine Immune Sciences Inc's Revenue amounts to 58.9m USD.
What is Alpine Immune Sciences Inc's Revenue growth rate?
Revenue CAGR 5Y
142%
Over the last year, the Revenue growth was 96%. The average annual Revenue growth rates for Alpine Immune Sciences Inc have been 85% over the past three years , 142% over the past five years .